Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
University Hospital, Toulouse
80 participants
Feb 1, 2022
INTERVENTIONAL
Conditions
Summary
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.
Eligibility
Inclusion Criteria4
- For cases:
- Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)
- Admitted for right ventricle electrophysiologic mapping
- For controls * Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.
Exclusion Criteria3
- Diagnostic of systemic chronic inflammatory disease
- Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.
- Taking immunosuppressant or immunomodulating medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube
Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05209776